Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 6/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | GRK5 | P34947 | 4/20 | 0.43 |
| ▸ | GRK2 | P25098 | 3/20 | 0.43 |
| ▸ | MET | P08581 | 4/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12539052 | 0.94 | MAP4K3 (0.55) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL10100802 | 0.92 | JAK2 (0.44) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL10100665 | 0.91 | MET (0.41) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL10100695 | 0.90 | JAK2 (0.43) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL10100662 | 0.90 | JAK2 (0.42) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL12538908 | 0.89 | JAK2 (0.50) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL10100624 | 0.88 | MAP4K3 (0.43) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL10100804 | 0.87 | MET (0.43) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL12538879 | 0.86 | MAP4K3 (0.47) | MAP4K3JAK2JAK1JAK3TYK2 | |
| SCHEMBL10100465 | 0.86 | JAK2 (0.45) | JAK2JAK1JAK3TYK2GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | MAP4K3 164/4885JAK2 59/4885JAK1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.